OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients
Issued by the Japanese Patent OfficeA New Protection Covering Tedopi® Until 2037 NANTES, France, Jan….
Sixty-Six Capital Expands Effective Bitcoin Exposure with Option for up to 200 BTC and Move to Direct Holdings
NTG Clarity to Announce Second Quarter Financial Results on August 27, 2026 with Earnings Call to Follow
SonicStrategy Reports Q2 2026 Staking Revenue and Reduced Monthly Burn
QSE Closes Second Tranche of Private Placement of $6 Million
BIGG Digital Assets Announces Name Change to Surge Digital Inc. and Share Consolidation